BOSTON--(BUSINESS WIRE)-ClinicalStudyDataRequest.com (CSDR), a cross-industry initiative providing researchers with access to clinical trial data from 13 major pharmaceutical companies, including trials that involve multiple sponsors, has increased the number of trials available to more than 3,460.
The available trials span all major disease areas. For example, there are over 360 diabetes and 240 asthma trials listed. Since the initiative was launched, there have been 335 requests from researchers for trial data.
CSDR offers medical and scientific researchers an array of clinical trial data to facilitate collaboration, advance scientific knowledge, and improve outcomes for patients. Through this portal, researchers can request anonymized patient-level data from the list of clinical trials via an independent process managed by the Wellcome Trust.
“CSDR is proud to have reached these important milestones toward our goal of promoting scientific research by giving access to detailed, patient-level data. We are increasing the number of trials listed and making it easier to access the data. A further critical step this fall will be the unveiling of an enhanced web portal for researchers,” said Scott Martin, chair of the ClinicalStudyDataRequest.com Steering Committee.
Contact
KMR Group
Scott Martin
312.795.0400
smartin@kmrgroup.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.